Resultados de la búsqueda 251-260 of 12183 for Lymphatic filariasis

1. Cirugía - Ensayos clínicos - Mayo Clinic

   The purpose of this study is to better understand the anatomy of the lymphatic structure and the molecular process that leads to the over production of lymph ...

2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   The purpose of this study is to better understand the anatomy of the lymphatic structure and the molecular process that leads to the over production of lymph ...

3. Cirugía - Ensayos clínicos - Mayo Clinic

   The purpose of this study is to better understand the anatomy of the lymphatic structure and the molecular process that leads to the over production of lymph ...

4. Hematología - Ensayos clínicos - Mayo Clinic

   The purpose of this study is to compare the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden.

5. Hematología - Ensayos clínicos - Mayo Clinic

   The purpose of this study is to compare the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden.

6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   The purpose of this study is to better understand the anatomy of the lymphatic ... of lymph fluid. This proposal will begin intense lymphedema screening ...

7. Hematología - Ensayos clínicos - Mayo Clinic

   This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy ...

8. Hematología - Ensayos clínicos - Mayo Clinic

   The purpose of this study is to compare the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden.

9. Enfermedad de los vasos sanguíneos pequeños

   Ahmed B, et al. Alternative causes of myocardial ischemia in women: An update on spontaneous coronary artery dissection, vasospastic angina and coronary ...

10. Hematología - Ensayos clínicos - Mayo Clinic

    All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...